Examining the Impact of Real-World Evidence on Medical Product Development: A Three-Part Workshop Series

Workshop Three: Application

July 17 – 18, 2018

National Academy of Sciences Building, Lecture Room
2101 Constitution Ave. NW, Washington, DC 20418

The National Academies of Sciences, Engineering, and Medicine (National Academies) is convening a three-part workshop series, sponsored by FDA, examining how real-world evidence development and uptake can enhance medical product development and evaluation. The workshops will advance discussions and common knowledge about complex issues relating to the generation and utilization of real-world evidence, including fostering development and implementation of the science and technology of real-world evidence generation and utilization.

- **Workshop One (September 19-20, 2017)** focused on how to align incentives to support collection and use of real-world evidence in health product review, payment, and delivery. Incentives need to address barriers impeding the uptake of real-world evidence, including barriers to transparency.
- **Workshop Two (March 6-7, 2018)** illuminated what types of data are appropriate for what specific purposes and suggested practical approaches for data collection and evidence use by developing and working through example use cases.
- **Workshop Three (July 17-18, 2018)** will examine and suggest approaches for operationalizing the collection and use of real-world evidence through discussing and revising “decision aids” about specific topics in study design. The decision aids will be question lists to help inform stakeholders about study design choices, including potential risks, costs, and reporting/transparency expectations.

**DAY 1: July 17, 2018**

8:00 a.m.  Breakfast available outside the Lecture Room

8:15 a.m.  **Welcome and opening remarks**
**MARK MCCLELLAN, Workshop Series Co-Chair**
Director
Duke-Margolis Center for Health Policy

**GREGORY SIMON, Workshop Series Co-Chair**
Investigator
Kaiser Permanente Washington Health Research Institute
**SESSION I**  **KEY CONSIDERATIONS FOR REAL-WORLD EVIDENCE APPLICATION**

Session Objectives:

- Examine how some organizations are currently considering traditional and real-world evidence.
- Discuss factors that may be influencing overall cost and time investment required by traditional evidence generation.
- Consider when nontraditional datasources may be beneficial to assess outcomes.

8:45 a.m.  **Update on IMI’s GetReal and view from NICE**  
PALL JONSSON  
Associate Director, Research and Development  
National Institute for Health and Care Excellence

9:05 a.m.  **Drivers of expense and delay**  
ELLIOTT LEVY  
Senior Vice President, Global Development  
Amgen, Inc.

9:25 a.m.  **Patient-collected and owned data**  
KOMATHI STEM  
Chief Executive Officer and Founder  
monARC Bionetworks

9:45 a.m.  **BREAK**

**SESSION II**  **WHEN IS A REAL-WORLD DATA ELEMENT FIT FOR ASSESSMENT OF ELIGIBILITY, TREATMENT EXPOSURE, OR OUTCOMES?**

Session Objectives:

- Discuss potential bias-introducing steps in evidence generation from real-world data.
- Suggest key considerations in the data collection and evidence generation processes that influence reliability of RWD.
- Discuss how a decision aid laying out key questions and considerations might help inform current and future studies.

10:05 a.m.  **Introduction: A proposed framework for a decision aid**  
PALL JONSSON,  *Session Moderator*  
Associate Director, Research and Development  
National Institute for Health and Care Excellence

10:15 a.m.  **Looking back: How might a decision aid inform a real-world example?**  
JEFF ALLEN  
President and Chief Executive Officer  
Friends of Cancer Research
10:35 a.m.  **Looking forward: How decision aid might apply to future studies?**  
*Panel discussion and audience Q&A*  

**AYLIN ALTAN**  
Senior Vice President of Research  
OptumLabs

**ROBERT BALL**  
Deputy Director, Office of Surveillance and Epidemiology  
Center for Drug Evaluation and Research  
U.S. Food and Drug Administration

**LUCA FOSCHINI**  
Co-founder and Chief Data Scientist  
Evidation Health

**BRANDE YAIST**  
Sr. Director, Global Patient outcomes and Real-World Evidence  
Eli Lilly and Company

12:00 p.m.  **BREAK** (Lunch available Outside the Lecture Room)

---

**SESSION III  OBSCURING INTERVENTION ALLOCATION IN TRIALS TO GENERATE REAL-WORLD EVIDENCE: WHY, WHO, AND WHEN?**

**Session Objectives:**

- Discuss how variability in knowledge of treatment assignment group affects  
  - Provider and patient adherence and outcomes  
  - Study cost and reliability.
- Suggest key factors that could affect decisions to obscure intervention allocation.
- Discuss how a decision aid laying out key questions and considerations might help inform current and future studies.

1:00 p.m.  **Introduction: A proposed framework for a decision aid**  
**JONATHAN WATANABE, Session Moderator**  
Associate Professor of Clinical Pharmacy  
National Academy of Medicine Anniversary Fellow in Pharmacy  
University of California San Diego

1:10 p.m.  **Looking back: How might a decision aid inform a real-world example?**  
**JOHN GRAHAM**  
Head, Value Evidence and Outcomes  
GlaxoSmithKline

**ORLY VARDENY**  
Minneapolis VA Center for Chronic Disease outcomes Research  
Associate Professor of Medicine  
University of Minnesota
1:30 p.m.  Looking forward: How decision aid might apply to future studies?
Panel discussion and audience Q&A

CATHY CRITCHLOW
Vice President, Center for Observational Research
Amgen, Inc.

NANCY DREYER
Chief Scientific Officer
IQVIA

ALEX JOHN LONDON
Clara L. West Professor of Ethics and Philosophy
Carnegie Mellon University

JAMES P. SMITH
Deputy Director, Division of Metabolism and Endocrinology Products
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

2:50 p.m.  BREAK

SESSION IV  HOW TIGHTLY SHOULD INVESTIGATORS ATTEMPT TO CONTROL OR RESTRICT TREATMENT QUALITY IN A PRAGMATIC OR REAL-WORLD TRIAL?

Session Objectives:

• Discuss how variability in treatment delivery and adherence can affect results, including
  o Potential influence of variation in standard treatment practice, and
  o Considerations for balancing participant autonomy and safety.
• Suggest key factors that could help determine the base comparison and level of control suited to a particular trial.
• Discuss how a decision aid laying out key questions and considerations might help inform current and future studies.

3:10 p.m.  Introduction: A proposed framework for a decision aid
JENNIFER GRAFF, Session Moderator
Vice President of Comparative Effectiveness Research
National Pharmaceutical Council

3:20 p.m.  Looking back: How might a decision aid inform a real-world example?
LARRY ALPHS
Deputy Chief Medical Officer
Newron Pharmaceuticals
3:40 p.m.  **Looking forward: How decision aid might apply to future studies?**  
*Panel discussion and audience Q&A*  
**JUDITH CARRITHERS**  
Director of Regulatory Services  
Advarra

**W. BENJAMIN NOWELL**  
Director, Patient-Centered Research  
Global Healthy Living Foundation  
Co-PI: ArthritisPower Patient Powered Research Network

**PETER STEIN**  
Deputy Director, Office of New Drugs  
Center for Drug Evaluation and Research  
U.S. Food and Drug Administration

4:50 p.m.  **Day 1 wrap up and concluding thoughts/discussion with audience**

5:00 p.m.  **ADJOURN WORKSHOP DAY 1**
DAY 2: July 18, 2018

7:30 a.m.  Breakfast Available Outside the Lecture Room

8:00 a.m.  Welcome
MARK MCCLELLAN, Workshop Series Co-Chair
Director
Duke-Margolis Center for Health Policy

GREGORY SIMON, Workshop Series Co-Chair
Investigator
Kaiser Permanente Washington Health Research Institute

SESSION V  HOW CAN BIAS IN OBSERVATIONAL COMPARISONS BE ASSESSED AND MINIMIZED?

Session Objectives:

- Discuss methods to assess presence of and optimally reduce bias from unmeasured confounding.
- Suggest key considerations for assessing—and communicating—uncertainty in observational studies.
- Discuss how a decision aid laying out key questions and considerations might help inform current and future studies.

8:10 a.m.  Introduction: A proposed framework for a decision aid
DAVID MARTIN
Associate Director for Real-World Evidence Analytics
U.S. Food and Drug Administration

8:20 a.m.  Looking back: How might a decision aid inform a real-world example?
HECTOR IZURIETA
Epidemiologist, Office of Biostatistics and Epidemiology
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

8:40 a.m.  Looking forward: How decision aid might apply to future studies?
Panel discussion and audience Q&A
GREGORY DANIEL, Session Moderator
Deputy Director
Duke-Margolis Center for Health Policy

JESSICA FRANKLIN
Assistant Professor of Medicine
Harvard Medical School
**SESSION VI  FDA PANEL**

Session Objectives:

- Hear updates and perspective of current thinking about real-world evidence in Europe.
- Discuss challenges, opportunities, and remaining gaps for moving forward with real-world evidence application.

10:15 a.m.  **A European perspective**  
ALASDAIR BRECKENRIDGE,  *Session Moderator*  
Emeritus Professor of Clinical Pharmacology  
University of Liverpool

10:30 a.m.  **Reflections from FDA**  
STEVEN ANDERSON  
Director, Office of Biostat. and Epidem., Center for Biologics Evaluation and Research  
U.S. Food and Drug Administration

JACQUELINE CORRIGAN-CURAY  
Director, Office of Medical Policy, Center for Drug Evaluation and Research  
U.S. Food and Drug Administration

JEFF SHUREN  
Director, Center for Devices and Radiological Health  
U.S. Food and Drug Administration
11:15 a.m.  Panel discussion with audience

11:50 p.m.  Synthesis of workshop discussions
MARK MCCLELLAN, Workshop Series Co-Chair
Director
Duke-Margolis Center for Health Policy

GREGORY SIMON, Workshop Series Co-Chair
Investigator
Kaiser Permanente Washington Health Research Institute

12:00 p.m.  ADJOURN WORKSHOP DAY 2